참고문헌 (98)

1. Global Tuberculosis Control: surveillance, planning, financing. WHO Report 2004 

2. Jin BW. Chapter 15. Preventive treatment. In: Hong YP, Kim SJ, editors. Tuberculosis. 4th ed. Seoul: Korean National Tuberculosis Association,KoreanAcademy of Tuberculosis and Respiratory Diseases; 1993. p. 161-72 

3. Hong YP. Tuberculosis in Korea-yesterday, today and tomorrow. Tuberc Respir Dis 1997;44:1-10 

4. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am JRespir Crit Care Med 2000;161:S221-47 

5. Anti-Tuberculosis Drug Resistance in the World (Report No.2, Prevalence and Trends). WHO/CDS/TB/2000.278 

6. Korean National Institute of Health. Guidelines for the control of tuberculosis 2003 

7. Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patientpopulation. Clin Exp Rheumatol 1998;16:9-13 

8. Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol 2002;20: 127-32 

9. Kim SI, Kim MS, Kim YS, Park K. Is pulmonary tuberculosis a major risk factor on patient and graft survival in kidney transplantation? Transplant Proc 1997;29:820 

10. World Health Organization. Treatment of tuber culosis: guidelines for national programmes 2003 

11. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860 6 

12. Khan K, Muennig P, Behta M, Zivin JG. Global drug resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9 

13. Bai GH, Kim SJ, Lee EK, Lew WJ. Incidence of pulmonary tuberculosis in Korean civil servants: second study, 1992-1994. Int J Tuberc Lung Dis 2001;5:346-53 

14. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis 2003;7:912-9 

15. Korean National Institute of Health, Korean Institute of Tuberculosis. Annual report on the notified tuberculosis patients in Korea (2002.1- 2002.12). Seoul: Korean National Institute of Health, Korean Institute of Tuberculosis. 2003 

16. Lew WJ. Tuberculosis situation in Korea. Tuberc Respir Dis 1999;46:301-10 

17. Hong YP. Tuberculosis control in Korea. Hallym Health Forum. 1999;3:111-48 

18. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-7 

19. Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 1999;29:1524-8 

20. Rieder HL. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung Dis 2003;7:S333-6 

21. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-8 

22. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168-73 

23. Kim SJ, Bai GH, Lee H, Kim HJ, Lew WJ, Park YK, et al. Transmission of Mycobacterium tuber culosis among high school students in Korea. Int JTuberc Lung Dis 2001;5:824-30 

24. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration Cooperative Study XII. Chest 1978;73:44-8 

25. Steinbruck P, Dankova D, Edwards LB, Doster B, Livesay VT. The risk of tuberculosis in patients with fibrous lesions radiologically diagnosed. Bull Int Union Tuberc 1972;47:144-71 

26. Ministry of Health & Welfare, Korean National Tuberculosis Association. Report on the 7th tuberculosis prevalence survey in Korea. Seoul: Ministry of Health & Welfare, Korean National Tuberculosis Association. 1995 

27. Feldman WH, Baggenstoss AH. The residual infectivity of the primary complex of tuberculosis. Am J Pathol 1938;14:473-90 

28. Opie EL, ronson JD. Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Arch Pathol 1927;4:1-21 

29. Bateman ED. Is tuberculosis chemoprophylaxis necessary for patients receiving corticosteroids for respiratory disease? Respir Med 1993;87:485-7 

30. Park JS, Kim MS, Lee JH, Chang J, Kim SK, Jeon KO, et al. Mycobacterial infection after kidney transplantation: single center experience. J Korean Soc Transplant 2001;15:39-46 

31. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345: 1098-104 

32. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7 

33. Lee YS, Jung JO, Hong JH, Seo YI, Eom KS, Bhan JW, et al. Occurrence of tuberculous pleurisy associated with infliximab therapy. Korean J Med (inpress) 

34. American Thoracic Society/Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000;161:1376-95 

35. Koch R. An address on bacteriological research. BMJ 1890:380-83 

36. von Pirquet C. Frequency of tuberculosis in childhood JAMA 1907:675-78 

37. Iseman MD. A clinician's guide to tuberculosis. Philadelphia: Lippincott Williams & Wilkins.; 2000 

38. Orme IM, Cooper AM. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999; 20:307-12 

39. Seibert FB, Glenn JT. Tuberculin purified protein derivative; preparation and analysis of a large quantity for standard. Am Rev Tuberc 1941;44:1-25 

40. Sbarbaro JA. Skin test antigens: an evaluation whose time has come. Am Rev Respir Dis 1978; 118:1-5 

41. Magnusson M, Bentzon MW. Preparation of purified tuberculin RT 23. Bull World Health Organ 1958;19:829-43 

42. Comstock GW, Edwards LB, Philip RN, Winn WA. A Comparison in the United States of America of Two Tuberculins, Ppd-S and Rt 23. Bull World Health Organ 1964;31:161-70 

43. Bearman JE, Kleinman H, Glyer VV, Lacroix OM. A Study of Variability in Tuberculin Test Reading. Am Rev Respir Dis 1964;90:913-19 

44. Sokal JE. Editorial: Measurement of delayed skintest responses. N Engl J Med 1975;293:501-2 

45. Rose DN, Schechter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med 1995; 10:635-42 

46. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21 

47. Daniel TM, Janicki BW. Mycobacterial antigens: a review of their isolation, chemistry, and immuno logical properties. Microbiol Rev 1978;42:84-113 

48. Harboe M. Antigens of PPD, old tuberculin, and autoclaved Mycobacterium bovis BCG studied by crossed immunoelectrophoresis. Am Rev Respir Dis1981;124:80-7 

49. Bahrmand AR, Madani H, Samar G, Khalilzadeh L, Bakayev VV, Yaghli M, et al. Detection and identification of non-tuberculous mycobacterial infections in 6,472 tuberculosis suspected patients. Scand J Infect Dis 1996;28:275-8 

50. Bass JBJ. The tuberculin test. In: Hershfield. LBRaES, Editor. Tuberculosis. ed. New York: Mercel Decker; 1993. p. 145 

51. Margileth AM. The use of purified protein derivative mycobacterial skin test antigens in children and adolescents: purified protein derivative skin test results correlated with mycobacterial isolates. Pediatr Infect Dis 1983;2:225-31 

52. Albertini M, Haas H, Chiche V, Bourrier T, Dage ville C, Mariani R. Non-specific tuberculin reactivity due to sensitization to non-tuberculous mycobacteria (NTM) in children not vaccinated with BCG. Diagnostic value of a comparison of intradermal tests with tuberculin and NTM antigens. Rev Mal Respir 1996;13:273-9 

53. Comstock GW, Edwards LB, Nabangxang H. Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am Rev Respir Dis 1971;103: 572-5 

54. Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and 5years among BCG vaccinated subjects. Bull World Health Organ 1972;47:49-58 

55. Karalliedde S, Katugaha LP, Uragoda CG. Tuber culin response of Sri Lankan children after BCG vaccination at birth. Tubercle 1987;68:33-8 

56. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-9 

57. Mazurek GH, Villarino ME, Cdc. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:15-8 

58. Mazurek GH, LoBue PA, Daley CL, Bernardo J,Lardizabal AA, Bishai WR, et al. Comparison of a whole-blood interferon gamma assay with tuber culin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-7 

59. Bellete B, Coberly J, Barnes GL, Ko C, Chaisson RE, Comstock GW, et al. Evaluation of a wholeblood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 2002;34:1449-56 

60. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of a new specific blood test and the skin test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9 

61. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection an interferon-gamma based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64 

62. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-93 

63. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-64 

64. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847-50 

65. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ 1966;35:509-26 

66. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophy laxis in Alaska. Am Rev Respir Dis 1967;95:935-43 

67. Comstock GW, Baum C, Snider DE, Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis1979;119:827-30 

68. Johnson JL, Okwera A, Hom DL, Mayanja H, Mu tuluuza Kityo C, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-47 

69. Lee HS, Song HS, Lee HK, Kim KH, Chung HS, Kim CK, et al. Isoniazid metabolism and its clinical implications in Koreans. Tuberc Respir Dis 1962;12:22-37 

70. Tuberculosis Chemotherapy Centre, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment ofpulmonary tuberculosis. Bull world Health Organ 1970;43:143-206 

71. Bartmann K, Freise G. Microbiologicully cleten mined isoniuzid concentrutions in the tissues of animcl and man. Beitr Klin Tuberk Spezif Tuberkulosefforsch 1963;127: 546-60 

72. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62 

73. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48 

74. Hong Kong Chest Service/Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemopro phylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41 

75. Polesky A, Farber HW, Gottlieb DJ, Park H, Levinson S, O'Connell JJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am JRespir Crit Care Med 1996;154:1473-7 

76. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71 

77. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997;337:801-8 

78. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrobial Agents Chemother 1992;36: 548-51 

79. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000;55:887-901 

80. Bandyopadhyay T, Murray H, Metersky ML. Costeffectiveness of tuberculosis prophylaxis after release from short-term correctional facilities. Chest 2002;121:1771-5 

81. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuber culosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-50 

82. Medinger A. Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis. Chest. 2002;121:1710-2 

83. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7 

84. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuber culosis infection-New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001;50:289-91 

85. American Thoracic Society/Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recom mendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9 

86. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. JAMA 2001;286:1445-6 

87. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50: 733-5 

88. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. JAMA 2002;288:2967 

89. Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002;51:998-9 

90. Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002;288: 165-6 

91. Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D. Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest 2002; 122:1292-8 

92. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002;6:995-1000 

93. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167:824-7 

94. McNeill L, Allen M, Estrada C, Cook P. Pyrazin amide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003;123:102-6 

95. Papastavros T, Dolovich LR, Holbrook A, White head L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. Can Med Assoc J 2002;167:131-6 

96. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-7 

97. Bergeron KG, Bonebrake RG, Allen C, Gray CJ. Latent tuberculosis in pregnancy: screening and treatment. Curr Womens Health Rep 2003;3:303-8 

98. Nolan CM, Goldberg SV. Treatment of isoniazidresistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 2002;6:952-8 

저자의 다른 논문 :

심태선 (111) 고원중 (67) 임재준 (26) 류우진 (36)